Carried interest has survived more political cycles than most asset classes. The current pressure on its tax treatment is real, but the structural responses already in motion tell the more useful story.

What the current treatment actually looks like

Under present U.S. law, carried interest received by a GP is taxed as long-term capital gain, provided the underlying assets are held for more than three years. That three-year holding period was inserted by the Tax Cuts and Jobs Act of 2017, extending the prior one-year threshold. The top federal rate on long-term capital gains sits at 20 percent, plus the 3.8 percent net investment income tax for high earners, versus 37 percent on ordinary income.

The differential is meaningful at scale. On a $50 million carry check, the spread between capital gains treatment and ordinary income treatment represents several million dollars in federal liability alone, before state tax exposure. This is not a rounding error in partnership economics.

Where the political pressure is concentrated

The Inflation Reduction Act of 2022 came close. A carried interest provision clearing the Senate would have extended the holding period requirement from three to five years for real estate and buyout funds. It was stripped in final negotiations, largely at the insistence of Senator Kyrsten Sinema. The political coalition to actually legislate this has repeatedly failed to assemble, but the directional pressure has not reversed.

The current environment features a narrower congressional majority and a Republican-led chamber less inclined toward GP tax increases, but Treasury has independent rulemaking tools. Proposed regulations under Section 1061 issued in 2020 and finalized in 2021 already tightened several interpretations around API gains and lookthrough rules for S-corps and trusts. The regulatory perimeter is moving even when statutory change stalls.

How GPs are responding structurally

The observable responses fall into three categories. First, some managers are renegotiating LP agreements to characterize a portion of GP economics as a management fee offset arrangement, converting what would be carry into fee income deliberately, to control the composition of their taxable income profile. Second, co-investment structures are being used more deliberately to shift GP exposure toward assets with cleaner long-term capital gain timelines, isolating carry vehicles where hold periods are predictable.

Third, and more structurally significant, is the continued migration of GP economics into permanent capital vehicles. Publicly traded GP entities, such as those structured under partnership or corporate formats by several large alternative managers, treat economics differently at the entity level. Once GP economics flow through a publicly traded partnership or a C-corp holding company, the character and timing of taxation shifts considerably. This is not a workaround, it is a structural redesign of how GP compensation is constructed and reported.

• Holdco and C-corp GP entity formations are increasing among mid-market managers planning for succession or institutional LP requirements
• Three-year hold period compliance is being built into fund mandate language explicitly, reducing interpretive risk
• Some fund counsel are revisiting profits interest grant timing relative to asset acquisition dates to manage Section 1061 exposure

The operator read

The legislative path to changing carry taxation remains narrow and has failed repeatedly despite genuine political will on one side. The more immediate risk is incremental regulatory tightening at Treasury, which requires no vote. GPs operating at meaningful scale are not waiting for legislative clarity before restructuring how their economics are packaged and held.

The structural adaptation is already underway. The question for capital allocators reviewing GP economics is not whether carry will be taxed differently eventually, but whether the GP entities they are backing have the sophistication to manage that transition when it arrives.